China National Drug Administration approves Gilead Sciences' (NASDAQ:GILD) Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1 infection.
Genvoya is the first TAF-based single tablet regimen for the treatment of HIV to be approved in China. In the U.S., Genvoya has a boxed warning in its label regarding the risks of hepatitis B post treatment.
Shares are up a fraction premarket.
Subscribe for full text news in your inbox